The proinflammatory cytokines TNF-α and IL-1β impair economy of contraction in human myocardium

Cytokine

Volumn 39, Issue 3, 2007, Pages 157-162

  Hofmann, U ^a   Heuer, S ^a   Meder, K ^a   Boehler, J ^a   Lange, V ^a   Quaschning, T ^b   Ertl, G ^a   Bonz, A ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Energy metabolism; IL 1 ; Myocardium; Proinflammatory cytokines; TNF

Indexed keywords

INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; HEART FAILURE; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HUMAN TISSUE; INOTROPISM; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; ANIMALS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; ISOMETRIC CONTRACTION; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXYGEN CONSUMPTION; RATS; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS;

EID: 35349030836     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2007.07.185     Document Type: Article

References (25)

1. Gilles S., Zahler S., Welsch U., Sommerhoff C.P., and Becker B.F. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res 60 (2003) 608-616
2. Mann D.L. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65 (2003) 81-101
3. Seko Y., Takahashi N., Oshima H., Shimozato O., Akiba H., Kobata T., et al. Expression of tumour necrosis factor (TNF) receptor/ligand superfamily co-stimulatory molecules CD40, CD30L, CD27L, and OX40L in murine hearts with chronic ongoing myocarditis caused by coxsackie virus B3. J Pathol 188 (1999) 423-430
4. Azzawi M., Hasleton P.S., and Hutchinson I.V. TNF-alpha in acute cardiac transplant rejection. Cytokines Cell Mol Ther 5 (1999) 41-49
5. Reinhart K., and Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 29 (2001) S121-S125
6. Kadokami T., Frye C., Lemster B., Wagner C.L., Feldman A.M., and McTiernan C.F. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 104 (2001) 1094-1097
7. Gurantz D., Yndestad A., Halvorsen B., Lunde O.V., Omens J.H., Ueland T., et al. Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling. Cardiovasc Res 67 (2005) 106-115
8. Berthonneche C., Sulpice T., Boucher F., Gouraud L., de Leiris J., O'Connor S.E., et al. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol 287 (2004) H340-H350
9. Hofmann U., Domeier E., Frantz S., Laser M., Weckler B., Kuhlencordt P., et al. Increased myocardial oxygen consumption by TNF-alpha is mediated by a sphingosine signaling pathway. Am J Physiol Heart Circ Physiol 284 (2003) H2100-H2105
10. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
11. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
12. Aderka D., Engelmann H., Maor Y., Brakebusch C., and Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175 (1992) 323-329
13. Scallon B.J., Trinh H., Nedelman M., Brennan F.M., Feldmann M., and Ghrayeb J. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine 7 (1995) 759-770
14. Meyer M., Keweloh B., Guth K., Holmes J.W., Pieske B., Lehnart S.E., et al. Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new method for the measurement of oxygen consumption in musclestrip preparations. J Mol Cell Cardiol 30 8 (1998) 1459-1470
15. Kumar A., Thota V., Dee L., Olson J., Uretz E., and Parrillo J.E. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 183 (1996) 949-958
16. Frangogiannis N.G., Smith C.W., and Entman M.L. The inflammatory response in myocardial infarction. Cardiovasc Res 53 (2002) 31-47
17. Thielmann M., Dorge H., Martin C., Belosjorow S., Schwanke U., van De Sand A., et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 90 (2002) 807-813
18. Bonz A.W., Lengenfelder B., Jacobs M., Strotmann J., Held S., Ertl G., et al. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. Am Heart J 145 (2003) 693-699
19. Yokoyama T., Arai M., Sekiguchi K., Tanaka T., Kanda T., and Suzuki T. Tumor necrosis factor-alpha decreases the phosphorylation level of phospholamban and troponin I in spontaneously beating rat neonatal myocytes. J Mol Cell Cardiol 31 (1999) 261-273
20. Movsesisn M., and Schwinger R. Calcium sequestration by the sarcoplasmatic reticulum in heart failure. Cardiovasc Res 37 (1998) 352-359
21. 2+-atpase by cyclopiazonic acid in rat left ventricles. Jpn J Physiol 51 (2001) 99-108
22. Miyano Hiroshi M., ShishidoToshiaki M., Kawada T.M., MiyashitaHiroshi M., Sato Takayuki M., Sugimachi Masaru M., et al. Acute effect of tumor necrosis factor-alpha is minimal on mechanics but significant on energetics in blood-perfused canine left ventricles. Critical Care Medicine 27 (1999) 168-176
23. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., and Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33 (2006) 2398-2408
24. Nicola P.J., Maradit-Kremers H., Roger V.L., Jacobsen S.J., Crowson C.S., Ballman K.V., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 52 (2005) 412-420
25. Nicola P.J., Crowson C.S., Maradit-Kremers H., Ballman K.V., Roger V.L., Jacobsen S.J., et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 54 (2006) 60-67